03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
22:50 , Apr 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies suggest CAR T cell therapies targeting CEACAM5 could help treat neuroendocrine prostate cancer. Bioinformatics analysis of 7,555 human cell surface proteins, and transcriptomic and proteomic analyses of eight human...
22:53 , Apr 23, 2018 |  BC Extra  |  Preclinical News

CAR T against cell surface proteins to treat prostate cancer

Researchers at University of California Los Angeles identified cell surface targets to treat prostate adenocarcinoma and neuroendocrine prostate cancer, two distinct major subtypes of advanced prostate cancer, and suggested that CAR T cell therapy against...
23:25 , Mar 2, 2018 |  BioCentury  |  Product Development

Clever pegylation pay off

Nektar Therapeutics’ clever pegylation strategy allowed it to finesse the PK and dial down the toxicity of IL-2, turning a validated but problematic immuno-oncology mechanism into a viable candidate. The approach snagged a record-breaking deal...
01:21 , Jan 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer; lung cancer Mouse studies suggest IL-18-secreting CAR T cells could help treat pancreatic and lung cancers. In a mouse model of pancreatic cancer, CAR T cells targeting CEA and engineered to release...
00:19 , Oct 20, 2017 |  BC Innovations  |  Product R&D

Fighting cancer by mouth

With its first compound through Phase I, Vaximm AG has started to unveil the data and technology behind its preclinical pipeline of oral cancer vaccines. Using an attenuated Salmonella strain, the company is building a...
19:19 , Jun 2, 2017 |  BC Week In Review  |  Company News

Sanofi, Immunogen amend financials of ADC deals

In exchange for $30 million, ImmunoGen Inc. (NASDAQ:IMGN) and Sanofi (Euronext:SAN; NYSE:SNY) eliminated potential milestone and royalties payments the biotech was eligible to receive under two deals involving five compounds. The candidates are isatuximab, SAR408701...
00:28 , May 2, 2017 |  BC Week In Review  |  Clinical News

Targovax starts Ph Ib of TG02 in rectal cancer

Targovax A/S (OSE:TRVX) began a Phase Ib trial to evaluate TG02 in about 20 patients with locally recurrent Ras-mutated rectal cancer scheduled for surgery. In the first part, 10 patients will receive TG02 plus GM-CSF...
16:52 , Apr 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; cancer Mouse studies suggest promoting CEA expression with bovine papilloma pseudovirus could help treat colorectal and other cancers. The pseudovirus was composed of the bovine papillomavirus major caption protein L1 that targeted...